10x Genomics, Inc. (TXG) Financial Statements
Industry: Laboratory Analytical Instruments
In fiscal 2025, 10x Genomics reported revenue of $642.8M, up 5.2% from $610.8M the year before. Net income was -$43.5M (a -6.8% net margin), or -$0.35 per diluted share. Gross margin was 69.1% and operating margin was -9.5%. Operating activities generated $136.1M of cash, leaving $130.1M of free cash flow. At fiscal year end, 10x Genomics held $1.04B in total assets against $245.0M in total liabilities.
Open the full interactive 10x Genomics financials → Quarterly statements, key ratios, valuation history and price charts.
10x Genomics Key Stats
| Share Price | $71.79 |
|---|---|
| Market Cap | $9.33B |
| Revenue YoY Growth | +5.2% |
| 52-Week Range | $11.54 – $97.74 |
| Shares Outstanding | 130.0 million (basic, 2026 Q2) |
10x Genomics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $298.8M | $490.5M | $516.4M | $618.7M | $610.8M | $642.8M |
| Gross Profit | $240.4M | $416.4M | $396.0M | $409.3M | $414.5M | $443.9M |
| Operating Income | -$534.1M | -$52.3M | -$167.9M | -$265.3M | -$194.6M | -$61.0M |
| Pre-Tax Income | -$534.5M | -$53.7M | -$162.0M | -$248.8M | -$177.7M | -$39.9M |
| Income Tax | $8.3M | $4.5M | $4.0M | $6.3M | $4.9M | $3.6M |
| Net Income | -$542.7M | -$58.2M | -$166.0M | -$255.1M | -$182.6M | -$43.5M |
| Diluted EPS | -$5.37 | -$0.53 | -$1.46 | -$2.18 | -$1.52 | -$0.35 |
10x Genomics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $149.0M | $166.0M | $150.8M | $151.0M |
| Net Income | -$27.5M | -$16.3M | -$13.5M | -$17.9M |
| Diluted EPS | -$0.22 | -$0.13 | -$0.10 | -$0.14 |
10x Genomics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $663.6M | $587.4M | $219.7M | $359.3M | $344.1M | — |
| Current Assets | $774.4M | $747.6M | $635.0M | $596.0M | $584.4M | $684.5M |
| Total Assets | $929.3M | $1.02B | $1.03B | $965.1M | $918.6M | $1.04B |
| Current Liabilities | $118.1M | $110.4M | $131.0M | $127.2M | $117.6M | $153.5M |
| Total Liabilities | $190.3M | $201.3M | $223.2M | $224.1M | $208.5M | $245.0M |
| Shareholders' Equity | $739.1M | $817.6M | $805.7M | $741.0M | $710.1M | $796.3M |
10x Genomics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$217.9M | -$21.4M | -$33.6M | -$15.2M | $6.7M | $136.1M |
| Cash From Investing | -$38.4M | -$106.7M | -$350.9M | $133.5M | -$32.6M | -$13.4M |
| Cash From Financing | $468.9M | $35.3M | $15.8M | $13.7M | $10.9M | $6.8M |
| Free Cash Flow | -$254.6M | -$122.7M | -$165.3M | -$63.8M | -$5.7M | $130.1M |
Figures from 10x Genomics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full 10x Genomics financials page for every line item.
10x Genomics Company Profile
| Ticker | TXG |
|---|---|
| Exchange | Nasdaq |
| Industry | Laboratory Analytical Instruments |
| Headquarters | Pleasanton, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001770787 |
Frequently Asked Questions
What was 10x Genomics' revenue in fiscal 2025?
10x Genomics (TXG) reported revenue of $642.8M for fiscal 2025.
What is 10x Genomics' annual revenue history?
10x Genomics' annual revenue by fiscal year: 2020: $298.8M; 2021: $490.5M; 2022: $516.4M; 2023: $618.7M; 2024: $610.8M; 2025: $642.8M.
What was 10x Genomics' net income in fiscal 2025?
10x Genomics reported net income of -$43.5M for fiscal 2025.
What was 10x Genomics' earnings per share (EPS) in fiscal 2025?
10x Genomics' diluted EPS was -$0.35 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did 10x Genomics generate in fiscal 2025?
10x Genomics generated $130.1M of free cash flow in fiscal 2025.
What was 10x Genomics' revenue last quarter?
In its most recent reported quarter (2026 Q2), 10x Genomics reported revenue of $151.0M.
How many shares of 10x Genomics are outstanding?
10x Genomics reported a weighted average of 130.0 million basic shares outstanding in 2026 Q2.
What is 10x Genomics' market cap?
Based on its latest closing price, 10x Genomics (TXG) has a market capitalization of about $9.33B.
When does 10x Genomics' fiscal year end?
10x Genomics' fiscal year end, as registered with the SEC, is December 31.
Where is 10x Genomics headquartered?
10x Genomics lists its business address in Pleasanton, California in its SEC filings.